Journal of Renal Nutrition
Volume 17, Issue 4 , Pages 225-234 , July 2007

Caffeine and the Kidney: What Evidence Right Now?

References 

  1. Barone JJ, Roberts HR. Caffeine consumption. Food Chem Toxicol. 1996;34(1):119–129
  2. Massey LK. Caffeine and the elderly. Drugs Aging. 1998;13(1):43–50
  3. Butcher RW, Sutherland EW. Adenosine 3′,5′-phosphate in biological materials (I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine). J Biol Chem. 1962;237:1244–1250
  4. Snyder SH, Katims JJ, Annau Z, Bruns RF, Daly JW. Adenosine receptors and behavioral actions of methylxanthines. Proc Natl Acad Sci U S A. 1981;78(5):3260–3264
  5. Daly JW, Butts-Lamb P, Padgett W. Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell Mol Neurobiol. 1983;3(1):69–80
  6. Cuypers Y. Influence of caffeine and histamine on blood flow in artificially perfused kidneys. Arch Int Physiol Biochim. 1958;66(3):457–459
  7. Kincaid-Smith P, Saker BM, McKenzie IF. Lesions in the vasa recta in experimental analgesic nephropathy. Lancet. 1968;1(7532):24
  8. Prescott LF. Effects of acetylsalicylic acid, phenacetin, paracetamol and caffeine on renal tubular epithelium. Lancet. 1965;19:91–95
  9. Dorfman LJ, Jarvik ME. Comparative stimulant and diuretic actions of caffeine and theobromine in man. Clin Pharmacol Ther. 1970;11(6):869–872
  10. Massey LK, Wise KJ. The effect of dietary caffeine on urinary excretion of calcium, magnesium, sodium and potassium in healthy young females. Nutr Res. 1984;4:43–50
  11. Blanchard J, Sawers SJ. Relationship between urine flow rate and renal clearance of caffeine in man. J Clin Pharmacol. 1983;23(4):134–138
  12. Trang JM, Blanchard J, Conrad KA, Harrison GG. Relationship between total body clearance of caffeine and urine flow rate in elderly men. Biopharm Drug Dispos. 1985;6(1):51–56
  13. Gillot I, Gouyon JB, Guignard JP. Renal effects of caffeine in preterm infants. Biol Neonate. 1990;58(3):133–136
  14. Grandjean AC, Reimers KJ, Bannick KE, Haven MC. The effect of caffeinated, non-caffeinated, caloric and non-caloric beverages on hydration. J Am Coll Nutr. 2000;19(5):591–600
  15. Armstrong LE, Pumerantz AC, Roti MW, et al. Fluid, electrolyte, and renal indices of hydration during 11 days of controlled caffeine consumption. Int J Sport Nutr Exerc Metab. 2005;15(3):252–265
  16. Izzo JL, Ghosal A, Kwong T, Freeman RB, Jaenike JR. Age and prior caffeine use alter the cardiovascular and adrenomedullary responses to oral caffeine. Am J Cardiol. 1983;52(7):769–773
  17. Passmore AP, Kondowe GB, Johnston GD. Renal and cardiovascular effects of caffeine: a dose-response study. Clin Sci (Lond). 1987;72(6):749–756
  18. Maughan RJ, Griffin J. Caffeine ingestion and fluid balance: a review. J Hum Nutr Diet. 2003;16(6):411–420
  19. Neuhauser-Berthold M, Beine S, Verwied SC, Luhrmann PM. Coffee consumption and total body water homeostasis as measured by fluid balance and bioelectrical impedance analysis. Ann Nutr Metab. 1997;41(1):29–36
  20. Bellet S, Roman L, DeCastro O, Kim KE, Kershbaum A. Effect of coffee ingestion on catecholamine release. Metabolism. 1969;18(4):288–291
  21. Wemple RD, Lamb DR, McKeever KH. Caffeine vs caffeine-free sports drinks: effects on urine production at rest and during prolonged exercise. Int J Sports Med. 1997;18(1):40–46
  22. Rieg T, Steigele H, Schnermann J, Richter K, Osswald H, Vallon V. Requirement of intact adenosine A1 receptors for the diuretic and natriuretic action of the methylxanthines theophylline and caffeine. J Pharmacol Exp Ther. 2005;313(1):403–409
  23. Shirley DG, Walter SJ, Noormohamed FH. Natriuretic effect of caffeine: assessment of segmental sodium reabsorption in humans. Clin Sci (Lond). 2002;103(5):461–466
  24. Nussberger J, Mooser V, Maridor G, Juillerat L, Waeber B, Brunner HR. Caffeine-induced diuresis and atrial natriuretic peptides. J Cardiovasc Pharmacol. 1990;15(5):685–691
  25. Lee J, Ha JH, Kim S, Oh Y, Kim SW. Caffeine decreases the expression of Na+/K+-ATPase and the type 3 Na+/H+ exchanger in rat kidney. Clin Exp Pharmacol Physiol. 2002;29(7):559–563
  26. Massey LK, Sutton RA. Acute caffeine effects on urine composition and calcium kidney stone risk in calcium stone formers. J Urol. 2004;172(2):555–558
  27. Bergman EA, Massey LK, Wise KJ, Sherrard DJ. Effects of dietary caffeine on renal handling of minerals in adult women. Life Sci. 1990;47(6):557–564
  28. Zanardo V, Dani C, Trevisanuto D, et al. Methylxanthines increase renal calcium excretion in preterm infants. Biol Neonate. 1995;68(3):169–174
  29. Davies PM, Fairbanks LD, Safranow K, Bending MR, Simmonds HA. An unusual patient with kidney stones composed of 1-methyluric acid. Urol Res. 2006;34(1):58–60
  30. McPhee MD, Whiting SJ. The effect of adenosine and adenosine analogues on methylxanthine-induced hypercalciuria in the rat. Can J Physiol Pharmacol. 1989;67(10):1278–1282
  31. Massey LK, Whiting SJ. Caffeine, urinary calcium, calcium metabolism and bone. J Nutr. 1993;123(9):1611–1614
  32. Luo D, Sun H, Xiao RP, Han Q. Caffeine induced Ca2+ release and capacitative Ca2+ entry in human embryonic kidney (HEK293) cells. Eur J Pharmacol. 2005;509(2-3):109–115
  33. Shuster J, Finlayson B, Scheaffer RL, Sierakowski R, Zoltek J, Dzegede S. Primary liquid intake and urinary stone disease. J Chronic Dis. 1985;38(11):907–914
  34. Curhan GC, Willett WC, Rimm EB, Spiegelman D, Stampfer MJ. Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol. 1996;143(3):240–247
  35. Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Beverage use and risk for kidney stones in women. Ann Intern Med. 1998;128(7):534–540
  36. Mandel N. Mechanism of stone formation. Semin Nephrol. 1996;16(5):364–374
  37. Baggio B. Genetic and dietary factors in idiopathic calcium nephrolithiasis (What do we have, what do we need?). J Nephrol. 1999;12(6):371–374
  38. Wrenn KD, Oschner I. Rhabdomyolysis induced by a caffeine overdose. Ann Emerg Med. 1989;18(1):94–97
  39. Kamijo Y, Soma K, Asari Y, Ohwada T. Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia. Vet Hum Toxicol. 1999;41(6):381–383
  40. Holstege CP, Hunter Y, Baer AB, Savory J, Bruns DE, Boyd JC. Massive caffeine overdose requiring vasopressin infusion and hemodialysis. J Toxicol Clin Toxicol. 2003;41(7):1003–1007
  41. Walsh I, Wasserman GS, Mestad P, Lanman RC. Near-fatal caffeine intoxication treated with peritoneal dialysis. Pediatr Emerg Care. 1987;3(4):244–249
  42. Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ. The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2002;13(11):2723–2729
  43. Belibi FA, Reif G, Wallace DP, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int. 2004;66(3):964–973
  44. Tanner GA, Tanner JA. Chronic caffeine consumption exacerbates hypertension in rats with polycystic kidney disease. Am J Kidney Dis. 2001;38(5):1089–1095
  45. Tofovic SP, Kost CK, Jackson EK, Bastacky SI. Long-term caffeine consumption exacerbates renal failure in obese, diabetic, ZSF1 (fa-fa(cp)) rats. Kidney Int. 2002;61(4):1433-1344
  46. Tofovic SP, Rominski BR, Bastacky S, Jackso EK, Kost CK. Caffeine augments proteinuria in puromycin-aminonucleoside nephrotic rats. Ren Fail. 2000;22(2):159–179
  47. Schwabe U, Ukena D, Lohse MJ. Xanthine derivatives as antagonists at A1 and A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1985;330(3):212–221
  48. Lin SL, Chiang WC, Chen YM, Lai CF, Tsai TJ, Hsieh BS. The renoprotective potential of pentoxifylline in chronic kidney disease. J Chin Med Assoc. 2005;68(3):99–105
  49. Rodriguez-Moran M, Guerrero-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients—a randomized, equivalent trial. Clin Nephrol. 2005;64(2):91–97
  50. Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16(7):2119–2126
  51. Nanra RS, Kincaid-Smith P. Chronic effect of analgesics on the kidney. Prog Biochem Pharmacol. 1972;7:285–323
  52. Laska EM, Sunshine A, Mueller F, Elvers WB, Siegel C, Rubin A. Caffeine as an analgesic adjuvant. JAMA. 1984;251(13):1711–1718
  53. Cai Q, Dmitrieva NI, Michea LF, Rocha G, Ferguson D, Burg MB. Toxicity of acetaminophen, salicylic acid, and caffeine for first-passage rat renal inner medullary collecting duct cells. J Pharmacol Exp Ther. 2003;306(1):35–42
  54. Rengelshausen J, Lindenmaier H, Cihlar T, Walter-Sack I, Haefeli WE, Weiss J. Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine. Biochem Biophys Res Commun. 2004;320(1):90–94
  55. Sekine T, Miyazaki H, Endou H. Molecular physiology of renal organic anion transporters. Am J Physiol Renal Physiol. 2006;290(2):F251–F261
  56. Zhang WY. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Saf. 2001;24(15):1127–1142
  57. Fox JM, Siebers U. Caffeine as a promoter of analgesic-associated nephropathy—where is the evidence?. Fundam Clin Pharmacol. 2003;17(3):377–392
  58. Modlinger PS, Welch WJ. Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens. 2003;12(5):497–502
  59. Evans SM, Pinto Pereira LM, Addae JI. Neuroprotection by caffeine and pentoxifylline during experimental cerebral ischaemia. West Indian Med J. 1999;48(1):23–25
  60. McLaughlin GE, Kashimawo LA, Steele BW, Kuluz JW. Reversal of acute tacrolimus-induced renal vasoconstriction by theophylline in rats. Pediatr Crit Care Med. 2003;4(3):358–362
  61. McLaughlin GE, Schober M, Perez M, Ruiz P, Steele BW, Abitbol C. Benefit of theophylline administration in tacrolimus-induced nephrotoxicity in rats. Pediatr Nephrol. 2003;18(9):860–864Epub 2003 Jun 26
  62. McLaughlin GE, Alva MD, Egea M. Adenosine receptor antagonism in acute tacrolimus toxicity. Nephrol Dial Transplant. 2006;21:1961–1965Epub 2006 Mar 7
  63. Potier M, Aparicio M, Cambar J. Protective effect of three xanthine derivatives (theophylline, caffeine and pentoxifylline) against the cyclosporin A-induced glomerular contraction in isolated glomeruli and cultured mesangial cells. Nephron. 1997;77(4):427–434
  64. Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos. 2000;28(11):1317–1320
  65. Perazella MA. Pharmacologic options available to treat symptomatic intradialytic hypotension. Am J Kidney Dis. 2001;38(4 Suppl 4):S26–S36
  66. Sulowicz W, Radziszewski A. Pathogenesis and treatment of dialysis hypotension. Kidney Int Suppl. 2006;(104):S36–S39
  67. Gigli GL, Adorati M, Dolso P, et al. Restless legs syndrome in end-stage renal disease. Sleep Med. 2004;5(3):309–315
  68. Lui SL, Ng F, Lo WK. Factors associated with sleep disorders in Chinese patients on continuous ambulatory peritoneal dialysis. Perit Dial Int. 2002;22(6):677–682
  69. Grosso LM, Bracken MB. Caffeine metabolism, genetics, and perinatal outcomes: a review of exposure assessment considerations during pregnancy. Ann Epidemiol. 2005;15(6):460–466
  70. Denaro CP, Brown CR, Wilson M, Jacob P, Benowitz NL. Dose dependency of caffeine metabolism. Clin Pharmacol Ther. 1990;48:277–285

PII: S1051-2276(07)00045-3

doi: 10.1053/j.jrn.2007.02.006

Journal of Renal Nutrition
Volume 17, Issue 4 , Pages 225-234 , July 2007

Article Tools

* Image Usage & Resolution